NCT02280876View on ClinicalTrials.gov

Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2015

Study Completion Date

May 31, 2015

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

1 - Andrographis paniculata p/st extract

"Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.~Other Names:~• ApE tablets, EUROMED Specific. Santiago Chile."

DRUG

2 - Excipients

"Placebo 650mg tabs, 2/day, 365 days continuously.~Other Names:~• Excipients tablets EUROMED Specific. Santiago Chile"

Trial Locations (1)

5090000

Hospital Regional, Valdivia

All Listed Sponsors
collaborator

Comisión Nacional de Investigación Científica y Tecnológica

OTHER_GOV

collaborator

University of Chile

OTHER

lead

Universidad Austral de Chile

OTHER

NCT02280876 - Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS) | Biotech Hunter | Biotech Hunter